Sun, Sep 21, 2014, 1:25 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Oct 23, 2006 7:37 PM Flag

    S&P MAINTAINS STRONG BUY OPINION ON SHARES OF VERTEX PHARMACEUTICALS

    Thanks, emsem, for posting lots of useful information.

    The passage: " ... Also, a 72-week control arm might be required, which could extend the filing date. We see some risk to the clinical timeline..."
    brought us down here from 37 area.

    A 72-week control arm is irrational if control arm is the IFN+RBVN standard of care. How many patients can withstand such a long torture!

    From the front part of the SP passage, see that FDA thinking is that a short trial is OK if the efficacy is good.

    If 24-wk SVR is 75%, don't see who would dare demand 2 year IFN.

    I predict that SVR for patient with genotype 1 would be better than 83% with 950. This figure comes from the rate of hard-to-treat mutant occurance.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VRTX
103.75+6.40(+6.57%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.